Cognitive impairment in patients with arterial hypertension

Close metadata

Recommended articles:

The impact of therapy with Mexidol on neurological deficit and functional outcome in patients with ischemic stroke: a systematic review and meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(12-2):49-60

Arterial hypertension and cognitive impairment. Neurologist’s view. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(11):7-13

Recognan (citicoline) efficacy and safety in cognitive impairment correction of various nosological forms. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(11):22-28

An effect of ethylmethylhydroxypyridine succinate and ethylmethylhydroxypyridine malate on changes in mitochondrial function under conditions of focal cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(11):111-116

The effect of mexidol as part of complex therapy on the perception of life in patients with heart failure. Russian Journal of Cardiology and Cardiovascular Surgery. 2023;(6):642-652

Features of lipid, carbohydrate metabolism and adiponectin secretion in pregnant women with abdominal obesity and arterial hypertension. Russian Bulletin of Obstetrician-Gynecologist. 2023;(6-2):101-106

Results of a multicenter observational program to evaluate the effectiveness of complex therapy of patients with chronic cerebrovascular pathology with cognitive impairment with Cortexin and Neuromexol (CORNELia study). S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(12):34-41

Investigation of the effect of ethylmethylhydroxypyridine succinate on the effectiveness of non-steroidal anti-inflammatory drugs for visceral and somatic pain in mice and rats. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(12):124-132

Main causes of premature mortality due to obesity. Russian Journal of Preventive Medicine. 2023;(12):52-57

The use of Mexidol in patients with mild (moderate) cognitive impairment: results of a meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(1):82-88

Arterial hypertension (AH) is a leading risk factor for cardiovascular diseases including cerebrovascular complications. Strokes and/or vascular cognitive impairment (VCI) are considered as a clinical sign of brain damage as a target organ in hypertension. To identify and assess the severity of VCI, patients with hypertension should undergo a neuropsychological assessment. Neuroimaging confirm the vascular origin of cognitive impairment. Patient management should include antihypertensive therapy along with neuroprotection. Among different neuroprotective therapy, ethylmethylhydroxypyridine succinate (mexidol) is one of medication with serious evidence of clinical efficacy.

Keywords:

arterial hypertension

cognitive impairment

cerebral vascular disease

neuroprotection

ethylmethylhydroxypyridine succinate

mexidol

Authors:

Zaharov V.V.

Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0000-0002-8447-3264

Chernousov P.A.

Sechenov First Moscow Medical University (Sechenov University)

ORCID: 0000-0003-2143-1806

Vekhova K.A.

Sechenov First Moscow Medical University (Sechenov University)

ORCID: 0000-0003-0900-4721

Bogolepova A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

SPIN RSCI: 6775-0279
Scopus AuthorID: 6602240836
ORCID: 0000-0002-6327-3546

Received:

15.02.2024

Accepted:

16.02.2024

List of references:

Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J 2018;39(33):3021-3104. https://doi.org/10.1093/eurheartj/ehy339
Boytsov SA, Balanova YuA, Shalnova SA, et al. Arterial hypertension among individuals of 25—64 years old: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4-14. (In Russ.). https://doi.org/10.15829/1728-8800-2014-4-4-14
Kobalava ZhD, Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.). https://doi.org/10.15829/1560-4071-2020-3-3786
Zakharov VV, Vakhnina NV, Parfenov VA. Cognitive disorders and their treatment in hypertension. Meditsinskiy sovet = Medical Council. 2017;(1S):6-12. (In Russ.). https://doi.org/10.21518/2079-701X-2017-0-6-12
Starchina YuA, Zakharov VV. Cognitive impairment in hypertension. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(1):113-118. (In Russ.). https://doi.org/10.14412/2074-2711-2021-1-113-118
Meissner A. Hypertension and the Brain: A Risk Factor for More Than Heart Disease. Cerebrovasc Dis. 2016;42(3-4):255-262. https://doi.org/10.1159/000446082
Iadecola C, Gottesman RF. Neurovascular and Cognitive Dysfunction in Hypertension. Circ Res. 2019;124(7):1025-1044. https://doi.org/10.1161/CIRCRESAHA.118.313260
Shi Y, Thrippleton MJ, Makin SD, et al. Cerebral blood flow in small vessel disease: A systematic review and meta-analysis. J Cereb Blood Flow Metab. 2016;36:1653-1667. https://doi.org/10.1177/0271678X16662891
Zhetishev RR, Kamchatnov PR, Mikhailova NA, Ivashchenko AR. Prevalence and risk factors of asymptomatic cerebral infarction. The Clinician. 2015;9(1):13-17. (In Russ.). https://doi.org/10.17650/1818-8338-2015-1-13-17
Lei C, Deng Q, Li H, Zhong L. Association Between Silent Brain Infarcts and Cognitive Function: A Systematic Review and Meta-Analysis. J Stroke Cerebrovasc Dis. 2019;28(9):2376-2387. https://doi.org/10.1016/j.jstrokecerebrovasdis.2019.03.036
Qiu C, Cotch MF, Sigurdsson S, et al. Cerebral microbleeds, retinopathy, and dementia: the AGES-Reykjavik Study. Neurology. 2010;75(24):2221-2228. https://doi.org/10.1212/WNL.0b013e3182020349
Schmidt R, Schmidt H, Haybaeck J, et al. Heterogeneity in age-related white matter changes. Acta Neuropathol. 2011;122(2):171-185. https://doi.org/10.1007/s00401-011-0851-x
Smith EE, O’Donnell M, Dagenais G, et al. PURE Investigators. Early cerebral small vessel disease and brain volume, cognition and gait. Ann Neurol. 2015;77(2):251-261. https://doi.org/10.1002/ana.24320
Basile AM, Pantoni L, Pracucci G, et al. LADIS Study Group. Age, hypertension, and lacunar stroke are the major determinants of the severity of age-related white matter changes. The LADIS (Leukoaraiosis and Disability in the Elderly) Study. Cerebrovasc Dis. 2006;21(5-6):315-322. https://doi.org/10.1159/000091536
Wardlaw JM, Makin SJ, Valdés Hernández MC, et al. Blood-brain barrier failure as a core mechanism in cerebral small vessel disease and dementia: evidence from a cohort study. Alzheimers Dement. 2017;13(6):634-643. https://doi.org/10.1016/j.jalz.2016.09.006
LADIS Study Group. 2001—2011: a decade of the LADIS (Leukoaraiosis And DISability) Study: what have we learned about white matter changes and small-vessel disease? Cerebrovasc Dis. 2011;32(6):577-588. https://doi.org/10.1159/000334498
Jahno NN, Levin OS, Damulin IV. Comparison of clinical and MRI data in discirculatory encephalopathy. Message 2: cognitive impairment. Nevrologicheskij Zhurnal. 2001;6(3):10. (In Russ.).
Ostroumova TM, Parfenov VA, Ostroumova OD. Cognitive impairment in patients with arterial hypertension: a relationship with the level and daily blood pressure profile and pathogenetic mechanisms. Rational Pharmacotherapy in Cardiology. 2019;15(2):258-264. (In Russ.). https://doi.org/10.20996/1819-6446-2019-15-2-258-264
Hughes TM, Sink KM. Hypertension and Its Role in Cognitive Function: Current Evidence and Challenges for the Future. Am J Hypertens. 2016;29(2):149-157. https://doi.org/10.1093/ajh/hpv180
Langbaum JB, Chen K, Launer LJ, et al. Blood pressure is associated with higher brain amyloid burden and lower glucose metabolism in healthy late middle-age persons. Neurobiol Aging. 2012; 33:827.e11-827.e19 https://doi.org/10.1016/j.neurobiolaging.2011.06.020
Kim T, Yi D, Byun MS, et al. KBASE Research Group. Synergistic interaction of high blood pressure and cerebral beta-amyloid on tau pathology. Alzheimers Res Ther. 2022;14(1):193. https://doi.org/10.1186/s13195-022-01149-7
Snowdon DA, Greiner LH, Mortimer JA, et al. Brain infarction and the clinical expression of Alzheimer’s disease. The Nun Study. JAMA. 1997;277(10):813-817. https://doi.org/10.1001/jama.1997.03540340047031
Kulesh AA, Emelin AYu, Bogolepova AN, et al. Clinical manifestations and issues of diagnosis of chronic cerebrovascular disease (chronic cerebral ischemia) at an early (pre-dementia) stage. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(1):4-12. (In Russ.). https://doi.org/10.14412/2074-2711-2021-1-4-12
Zueva IB. Hypertension and cognitive impairments: Possible mechanisms of development, diagnosis, and approaches to therapy. Terapevticheskii Arkhiv. 2015;87(12):96-100. (In Russ.). https://doi.org/10.17116/terarkh2015871296-100
Launer LJ, Ross GW, Petrovitch H, et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging. 2000;21(1):49-55. https://doi.org/10.1016/s0197-4580(00)00096-8
Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ. 2001;322(7300):1447-1451. https://doi.org/10.1136/bmj.322.7300.1447
Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996;347(9009):1141-1145. https://doi.org/10.1016/s0140-6736(96)90608-x
Starchina YuA, Sleptcova KS. Treatment of cognitive impairment in arterial hypertension. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(5):90-95. (In Russ.). https://doi.org/10.14412/2074-2711-2021-5-90-95
Elias MF, Wolf PA, D’Agostino RB, et al. Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am J Epidemiol. 1993;138(6):353-364. https://doi.org/10.1093/oxfordjournals.aje.a116868
Kim H, Ang TFA, Thomas RJ, et al. Long-term blood pressure patterns in midlife and dementia in later life: Findings from the Framingham Heart Study. Alzheimers Dement. 2023;19(10):4357-4366. https://doi.org/10.1002/alz.13356
Sachdev P, Kalaria R, O’Brien J, et al. Internationlal Society for Vascular Behavioral and Cognitive Disorders. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28(3):206-218. https://doi.org/10.1097/WAD.0000000000000034
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed. Arlington: American Psychiatric Association, 2013.
Vakhnina NV. Cognitive disorders and therapy in patients with hypertension. Meditsinskiy sovet = Medical Council. 2014;(5):30-37. (In Russ.).
Román GC, Erkinjuntti T, Wallin A, et al. Subcortical ischaemic vascular dementia. Lancet Neurol. 2002;1(7):426-436. https://doi.org/10.1016/s1474-4422(02)00190-4
Fladd D. Subcortical vascular dementia. Geriatr Nurs. 2005;26(2):117-121. https://doi.org/10.1016/j.gerinurse.2005.01.001
Erkinjuntti T. Subcortical vascular dementia. Cerebrovasc Dis. 2002;13(suppl 2):58-60. https://doi.org/10.1159/000049152
Menon U, Kelley RE. Subcortical ischemic cerebrovascular dementia. Int Rev Neurobiol. 2009;84:21-33. https://doi.org/10.1016/S0074-7742(09)00402-4
Preobrazhenskaya IS, Yakhno NN. Vascular cognitive impairment — clinical manifestations, diagnostic approaches and treatment. Nevrologicheskii zhurnal. 2007;12(5):45-50. (In Russ.).
Zakharov VV. Povedencheskaya nevrologiya. M.: Profmedpress; 2022. (In Russ.).
Cristofori I, Cohen-Zimerman S, Grafman J. Executive functions. Handb Clin Neurol. 2019;163:197-219. https://doi.org/10.1016/B978-0-12-804281-6.00011-2
Zaharov VV, Vahnina NV. Cognitive disorders in arterial hypertension. Nervnye bolezni. 2013;3:16-21. (In Russ.).
Yakhno NN, Zakharov VV, Lokshina AB. The syndrome of moderate cognitive disorders in dyscirculatory encephalopathy. Zhurnal Neurologii i Psychiatrii im. S.S. Korsakova. 2005;105(2):13-17. (In Russ.).
Xie C, Zhong D, Zhang Y, et al. Prevalence and risk factors of cognitive impairment in Chinese patients with hypertension: a systematic review and meta-analysis. Front Neurol. 2024;14:1271437.
Yakhno NN, Levin OS, Damulin IV. Comparison of clinical and MRI data in dyscirculatory encephalopathy. Message 1: Motor disorders. Nevrologicheskij zhurnal. 2001;6(2):10-16. (In Russ.).
Bryzhakhina VG, Damulin IV. Statolocomotor disorders in elderly patients with dyscirculatory encephalopathy and dementia. Bulletin of practical neurology. 2003;7:17-21. (In Russ.).
Bryzhakhina VG, Damulin IV, Yakhno NN. Disturbances in walking and balance in dyscirculatory encephalopathy. Post 1. Neurological Journal. 2004;9:(2):11-16. (In Russ.).
Damulin IV, Bryzakhina VG, Shashkova EV, Yakhno NN. Disturbances in walking and balance in dyscirculatory encephalopathy. Message 2. Clinical, morphological and MRI comparisons. Neurological Journal. 2004;9(4):13-18. (In Russ.).
Borson S, Scanlan JM, Chen P, Ganguli M. The Mini-Cog as a screen for 248 dementia: Validation in a population-based sample. J Am Geriatr Soc. 2003;51:1451-1454. https://doi.org/10.1046/j.1532-5415.2003.51465.x
Folstein MF, Folstein SE, McHugh PR. «Mini-mental state». A practical method for grading the cognitive state of patients for the clinician. J Psych Res. 1975;12(3):189-198. https://doi.org/10.1016/0022-3956(75)90026-6
Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699. https://doi.org/10.1111/j.1532-5415.2005.53221.x
Zakharov VV, Voznesenskaya TG. Nervno-psikhicheskie narusheniya: diagnosticheskie testy. M.: MEDpress; 2013. (In Russ.).
Zakharov VV, Vakhnina NV, Gromova DO, et al. The clinical spectrum of non-dementia cognitive impairment: Subjective mild-to-moderate disorders. Neurology, Neuropsychiatry, Psychosomatics. 2015;7(4):83-91. (In Russ.). https://doi.org/10.14412/2074-2711-2015-4-83-91
Martynov AI, Tanashyan MM, Malyavin AG, et al. Resolution of the Council of Experts «Possibilities of neuroprotective therapy in patients with arterial hypertension and cognitive impairment». Therapy. 2023;9(10):148-158. (In Russ.). https://doi.org/10.18565/therapy.2023.10.148—158
Duering M, Biessels GJ, Brodtmann A, et al. Neuroimaging standards for research into small vessel disease-advances since 2013. Lancet Neurol. 2023;22(7):602-618. https://doi.org/10.1016/S1474-4422(23)00131-X
Haag MD, Hofman A, Koudstaal PJ, et al. Duration of antihypertensive drug use and risk of dementia: A prospective cohort study. Neurology. 2009;72(20):1727-1734. https://doi.org/10.1212/01.wnl.0000345062.86148.3f
Ostroumova OD, Parfenov VA, Ostroumova TM, et al. Expert consensus. Effect of antihypertensive therapy on cognitive functions. Systemic Hypertension. 2021;18(1):5-12. (In Russ.). https://doi.org/10.26442/2075082X.2021.1.200575
Iadecola C, Yaffe K, Biller J, et al. Impact of Hypertension on Cognitive Function: A Scientific Statement From the American Heart Association. Hypertension. 2016;68(6):e67-e94. https://doi.org/10.1161/HYP.0000000000000053
Piradov MA, Tanashyan MM, Domashenko MA. Neuroprotection in cerebrovascular diseases: the search for life on Mars or a promising direction of treatment. Part 1. Acute disorders of cerebral circulation. Annaly klinicheskoi i eksperimental’noi nevrologii. 2015;9(1):41-50. (In Russ.).
Piradov MA, Tanashyan MM, Domashenko MA, Maksimova MYu. Neuroprotection in cerebrovascular diseases: the search for life on Mars or a promising direction of treatment. Part 2. Chronic forms of cerebral circulation disorders. Annaly Klinicheskoi i Eksperimental’noi Nevrologii. 2015;9(3):10-19. (In Russ.).
Shchulkin AV. A modern concept of antihypoxic and antioxidant effects of mexidol. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2018;118(12-2):87-93. (In Russ.). https://doi.org/10.17116/jnevro201811812287
Fedin AI, Zaharov VV, Tanashyan MM, et al. Results of an international multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2021;121(11):7-16. (In Russ.). https://doi.org/10.17116/jnevro20211211117
Zakharov VV, Ostroumova OD, Kochetkov AI, et al. International multicenter randomized double-blind placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO): subanalysis in patients with arterial hypertension. Therapy. 2023;9(1):145-159. (In Russ.). https://doi.org/10.18565/therapy.2023.1.145-159

Close metadata